Effect of Intravenous Iron Supplementation on Celiac Disease Remission (IRONCEL)

NCT05114278 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2022-01-19

No results posted yet for this study

Summary

The study aims is to evaluate the efficacy of intravenous iron supplementation on celiac disease remission (total intestinal mucosal recovery). This randomized multicenter trial compare the administration of intravenous iron by infusion (Ferinject©: 15 mg/kg in NaCl solution in 30 min) and oral iron in combination; to patients receive only oral iron as standard care.

The first benefit with IV Iron supplementation is to correct iron deficiency more rapidly than oral iron alone because of trouble of absorption in case of intestinal villous atrophy.

Conditions

Interventions

DRUG

Ferinject

Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).

DRUG

oral iron

All patients will receive an oral iron supplementation (100mg/day).

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV
  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Georgia MALAMUT, MD, PhD · Cochin, AP-HP, Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2026-04-15
Completion
2026-04-15

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05114278 on ClinicalTrials.gov